Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) (OPTIRPE65)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02781480 |
Recruitment Status :
Recruiting
First Posted : May 24, 2016
Last Update Posted : December 18, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leber Congenital Amaurosis | Biological: AAV RPE65 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 27 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | AAV2/5-OPTIRPE65 |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA) |
Study Start Date : | April 2016 |
Estimated Primary Completion Date : | October 2018 |
Estimated Study Completion Date : | October 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Low dose AAV-RPE65
Subretinal administration of a single low dose of range AAV-RPE65
|
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65 |
Experimental: Intermediate dose AAV-RPE65
Subretinal administration of a single intermediate dose of range AAV-RPE65
|
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65 |
Experimental: High dose AAV-RPE65
Subretinal administration of a single high dose of range AAV-RPE65
|
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65 |
- Incidence of Adverse Events related to the treatment [ Time Frame: 1 year ]Safety is defined as the absence of ATIMP-related safety events
- Improvement in visual function [ Time Frame: 6 months ]Improvements in visual function as assessed by visual assessment
- Improvement in retinal function [ Time Frame: 6 months ]Improvements in retinal function as assessed by visual assessment
- Improvement in Quality of Life [ Time Frame: 6 months ]Quality of life will be measured by QoL questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Aged 3 years or older
- Early-onset severe retinal dystrophy consistent with RPE65 deficiency
Key Exclusion Criteria:
- Females who are pregnant or breastfeeding
- Have participated in another research study involving an investigational therapy for ocular disease within the last 6 months.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781480
Contact: Julie Bakobaki | julie.bakobaki@meiragtx.com | ||
Contact: Praseeda Thaikalloor | praseeda.thaikalloor@meiragtx.com |
United Kingdom | |
Moorfields Eye Hospital NHS Foundation Trust | Recruiting |
London, United Kingdom, EC1V 2PD | |
Contact: James Bainbridge j.bainbridge@ucl.ac.uk | |
Contact: Michel Michaelides michel.michaelides@ucl.ac.uk | |
Principal Investigator: James Bainbridge, Prof | |
Sub-Investigator: Michel Michaelides, Prof |
Responsible Party: | MeiraGTx UK II Ltd |
ClinicalTrials.gov Identifier: | NCT02781480 History of Changes |
Other Study ID Numbers: |
MGT003 |
First Posted: | May 24, 2016 Key Record Dates |
Last Update Posted: | December 18, 2017 |
Last Verified: | December 2017 |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
Blindness Leber Congenital Amaurosis Vision Disorders Sensation Disorders Neurologic Manifestations |
Nervous System Diseases Eye Diseases Signs and Symptoms Eye Diseases, Hereditary Retinal Diseases |